Clinical Trial

A Study to Learn How a Single Dose of the Study Medicine Called PF-08057418 is Tolerated in the Body of Healthy Adults.

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this clinical trial is to learn about the safety and pharmacokinetics (pharmacokinetics helps us understand how the drug is changed and eliminated from body after participant take it) of the study medicine (called PF-08057418) in healthy people. This study is seeking participants who are healthy adults. Everyone who participates in this study will receive the study medicine. The study medicine may be given as a solution or as a tablet. Participants will be dosed once a week for 5 weeks. The investigator will examine the experiences of people receiving the study medicine. This will help us determine if the study medicine is safe. Participants will be involved in this study for up to 13 weeks from screening to follow-up visit. Participants stay in the study clinic for the 5 week dosing duration of the study, with two follow-up visits subsequently, either in person or by telephone call.
Protocol Amendment History 2 changes
critical Trial completed 2026-07-25
critical Recruitment opened 2026-05-29
Trial Details
NCT Number NCT07575906
Lead Sponsor Pfizer
Conditions Healthy
Enrollment 8 participants
Start Date 2026-05-08
Primary Completion 2026-07-16 (estimated)
Study Completion 2026-07-16 (estimated)
Updated on ClinicalTrials.gov 2026-07-24